Noble Life Sciences is Granted Renewal of Full Accreditation from AAALAC
Noble Life Sciences is excited to announce the renewal of full accreditation from the Association...
Type 1 diabetes is an autoimmune disorder that affects nearly 347 million people worldwide.
The autoimmune disorder is characterised by the destruction of insulin-producing beta cells in the pancreas by the patient’s immune system. Because insulin regulates the metabolism of glucose, its absence results in dangerously elevated glucose levels in the blood.
Patients are dependent on insulin injections to regulate their blood glucose level, which must be constantly monitored throughout the day to avoid hypo or hyperglycemia. Even with careful management, Type 1 diabetes patients face the constant risk of the disease’s serious side effects, which include kidney failure, blindness, nerve damage, heart attack, stroke, and pregnancy complications.
Noble Life Sciences has optimised a streptozotocin (STZ) induced rat model of diabetes. This is the model of choice for preclinical development of therapeutic agents for diabetes.
Noble Life Sciences is excited to announce the renewal of full accreditation from the Association...
Implantable continuous infusion osmotic pumps have several applications in preclinical drug development. The pumps enable...
Noble Life Sciences will be exhibiting at this year's Society of Toxicology taking place in...